Medtronic announced on May 20 that it intends to acquire SPR Therapeutics for approximately $650 million in cash for the temporary peripheral nerve stimulation slot inside chronic pain, per the Medtronic newsroom release. Boston Scientific finished its own $533 million Nalu Medical acquisition earlier this year for the permanent micro-IPG slot, per the Boston Scientific newsroom. Nevro built the closed-loop AI overlay slot the prior year. Three shelf slots inside one chronic pain pathway, three different acquirers, and three different architectural decisions made years before the May 2026 deal that closed each one. The new entrant looking at the category today does not get to pick a slot the strategics have already claimed. The new entrant has to find the slot the incumbents cannot service from inside their existing portfolios and architect the business against that slot from the first product decision. Founders who finish in hard-tech do that slot-picking work before the engineering, regulatory, and commercial plan is sized, not after the first product is built.
If You Are Building a Company in This Environment
The default first-time hard-tech founder treats category positioning as a marketing problem. The team picks the technical differentiator that the engineering work is already producing, writes the positioning deck around it, and lets the market sort out which slot the device ends up in. The build-phase logic is that the product is what defines the slot, and the slot is what the launch documents will eventually describe. The cost of that logic shows up at the strategic-conversation stage, because the buy-side, the acquirer, and the large reference customer all read the device against the slots the incumbents have already claimed inside the category, not against the technical differentiator the marketing deck is leading with. The chronic pain category in May 2026 is the example. The strategics have now bought the temporary-PNS slot, the permanent micro-IPG slot, and the AI overlay slot. A new entrant pitching against any of those three is pitching against an incumbent that already owns the shelf.
Founders who finish do the slot-picking work as the first architectural decision inside the company, before the engineering plan is fixed. The starting question is which clinical or anatomical pocket inside the category the incumbents cannot service from inside their existing portfolios. The follow-on question is why the structural shape of the incumbent portfolio prevents them from credibly serving that pocket. The third question is what the regulatory pathway looks like for the slot the company is going to compete inside, and the fourth is what the commercial reference base looks like once the device is cleared. Only after those four questions are answered does the engineering, regulatory, and commercial plan get sized. The discipline is to refuse to design the device until the slot is settled, and to refuse to settle the slot until the incumbent portfolios are mapped against the pathway the company intends to enter.
The companies that stall in 2026 are the ones that pick the technically interesting device first, then try to retrofit a slot for it after the engineering is committed. The companies that compound past the strategics are the ones that picked the slot first, designed the device against that slot’s specific clinical and regulatory requirements, and walked into the first conversation with the buy-side or the acquirer carrying a coherent story about why the slot exists, why the incumbent cannot fill it, and how the company’s architecture proves both points at once.
What the Three Chronic Pain Slot Decisions Show
The Medtronic, Boston Scientific, and Nevro decisions are useful as a case study because each slot was claimed by a different kind of architectural choice. Medtronic picked the temporary-PNS slot because the existing Medtronic neuromodulation portfolio is anchored by permanent implants, and a 60-day step-down therapy with 50,000 prior implants from SPR plugs in front of the implanted product as a referral funnel. Boston Scientific picked the permanent micro-IPG slot because the existing Boston Scientific portfolio is built around the spinal cord stimulator and basivertebral nerve ablation lines, and Nalu’s smaller, peripheral form factor extends the same shelf without cannibalizing the SCS franchise. Nevro picked the closed-loop AI overlay slot because Nevro’s structural disadvantage against the two larger incumbents on form-factor and installed-base economics meant the company had to differentiate on the algorithmic layer, and Nevro spent years assembling the patient data flywheel the AI lane required. Each slot decision was a function of the incumbent’s prior architecture, not the device-level differentiator the marketing deck eventually described. The new entrant has to read the category the same way the acquirers do and pick a slot the existing architecture cannot reach.
The Five Questions for the Slot Decision
The five-question framework in Founders Who Finish reframes what a credible operating plan actually requires the team to deliver in a market where the strategics are consolidating around portfolio-shaped category shelves. Each question maps to an architectural decision that has to be settled before the engineering work is fixed, not after the first device is committed.
Question 1
What are you actually finishing?
If the answer is a single FDA clearance for a technically differentiated device, you are finishing a product, not a business. The finished business is a defensible slot inside the consolidating category that the incumbents cannot reach from inside their existing portfolios. Founders who finish identify the slot, document the architectural reason the incumbents cannot fill it, and size the operating plan against the slot rather than against the device.
Question 2
Who decides you are done?
The FDA reviewer, the payer setting the coverage determination, the strategic acquirer pricing the deal, and the reference customer committing to the device all read the slot rather than the device-level differentiator. A slot that fits the pathway the customer already walks through, the reimbursement the payer already covers, and the portfolio gap the acquirer already wants to close reads as a structurally different asset than the same device positioned against an undefined slot. Founders who finish design the architecture to read convincingly to all four decision-makers at once.
Question 3
What does your evidence actually prove?
The pivotal evidence has to do two things at once. The first is to prove the clinical and analytical claim required for the immediate FDA clearance. The second is to prove the slot claim against the incumbent portfolios. Evidence that compares the device only against a generic standard of care without addressing why the incumbents cannot replicate the result from inside their own portfolios leaves the slot claim undefended. Founders who finish design the pivotal to defend the slot, not only the label.
Question 4
What does your path to clearance, reimbursement, and commercial scale actually look like?
The path to clearance runs through a regulatory submission that frames the device against the slot. The path to reimbursement runs through a coverage strategy that fits inside the pathway the payer already pays for, not a new code that requires a fresh coverage determination. The path to commercial scale runs through reference customers who can articulate why the device fills a slot their current incumbent supplier cannot, and the path to strategic exit runs through acquirers whose existing portfolios have the structural gap the slot describes. Founders who finish run all four work streams against the same slot document and treat the slot decision as a structural input every plan inherits.
Question 5
What does the finish line look like to your buyer, your payer, and the investor pricing the round?
Strategic acquirers, payers, and investors pricing hard-tech in 2026 are reading consolidating categories at the shelf level, not the device level. The slot the company picks determines whether the device reads as the obvious bolt-on inside a coherent portfolio gap or as an orphan asset competing against the incumbents head-on. The chronic pain category in May 2026 is the visible version of the same dynamic that is consolidating interventional cardiology, surgical robotics, diagnostics, defense hardware, and physical AI. Founders who finish pick the slot first, design the company against it, and operate the build phase against the slot the strategics cannot reach.
Founders Who Finish
The guide for founders building in regulated and capital-intensive markets
The five-question framework for building medical device, diagnostics, AI SaMD, defense, climate, and other hard-tech companies that finish what they start, in the regulatory, capital, and operating environment as it actually exists.
Get the Book